OrderlyMeds vs Remedy Meds: November 2026 prices compared
As of November 20, 2026, from each program’s own page: on compounded tirzepatide, month to month and all-in, OrderlyMeds charges $299 a month and Remedy Meds $399 per 28-day cycle: $3,588 against $5,187 for a year, so OrderlyMeds costs $1,599 less over a year.
Released · Last reviewed · how we verify
On compounded semaglutide, month to month and all-in, OrderlyMeds charges $149 a month and Remedy Meds $299 per 28-day cycle: $1,788 against $3,887 for a year, so OrderlyMeds costs $2,099 less over a year.
OrderlyMeds and Remedy Meds, measure by measure
| Measure | OrderlyMeds | Remedy Meds |
|---|---|---|
| Tirzepatide, month to month | $299 (per month) | $399 (per 28-day cycle) |
| Tirzepatide, lowest printed | $149 (2-month new-customer offer, $299) | $399 (4-week supply; $279 first month only) |
| Semaglutide, month to month | $149 (per month) | $299 (per 28-day cycle) |
| Semaglutide, lowest printed | $74 (2-month new-customer offer, $149) | $299 (4-week supply; $179 first month only) |
| Dose pricing | same price at every dose | same price at every dose |
| Membership or program fee | none | none |
| Computed score | 27.9 of 40 (position 6 of 27) | 24.3 of 40 (position 7 of 27) |
| FDA warning letters | 728291 (2026-06-08) | 716830 (2025-09-09) |
| November 20 read | first-party read | first-party read |
Strengths and limitations: which fits whom
OrderlyMeds prints one price at every dose with no membership, so a dose increase does not change the bill. Remedy Meds prints one price at every dose with no membership, so a dose increase does not change the bill. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| OrderlyMeds | tirzepatide | — | $299 |
| OrderlyMeds | semaglutide | — | $149 |
| Remedy Meds | tirzepatide | — | $399 |
| Remedy Meds | semaglutide | — | $299 |
Regulatory record
FDA’s warning-letter index lists warning letter 728291 (dated June 8, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to OrderlyMeds; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 716830 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) to Remedy Meds; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, OrderlyMeds or Remedy Meds?
On compounded tirzepatide, month to month and all-in, OrderlyMeds charges $299 a month and Remedy Meds $399 per 28-day cycle: $3,588 against $5,187 for a year, so OrderlyMeds costs $1,599 less over a year. On compounded semaglutide, month to month and all-in, OrderlyMeds charges $149 a month and Remedy Meds $299 per 28-day cycle: $1,788 against $3,887 for a year, so OrderlyMeds costs $2,099 less over a year.
Do OrderlyMeds and Remedy Meds charge a membership fee?
OrderlyMeds: no membership fee; Remedy Meds: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are OrderlyMeds and Remedy Meds medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- OrderlyMeds pricing page (read November 20, 2026)
- Remedy Meds pricing page (read November 20, 2026)
- FDA warning letter 728291 to OrderlyMeds (dated 2026-06-08, posted 2026-06-16)
- FDA warning letter 716830 to Remedy Meds (dated 2025-09-09, posted 2025-09-16)